143.37 USD
-0.32 (-0.22%)
142.5 USD
-0.87 (-0.61%)
We assign a fundamental rating of 6 out of 10 to TMDX. TMDX was compared to 186 industry peers in the Health Care Equipment & Supplies industry. TMDX has an excellent financial health rating, but there are some minor concerns on its profitability. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year TMDX was profitable.
- TMDX had a positive operating cash flow in the past year.
- TMDX had negative earnings in 4 of the past 5 years.
- TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- TMDX's Return On Assets of 9.70% is amongst the best of the industry. TMDX outperforms 93.55% of its industry peers.
- With an excellent Return On Equity value of 25.84%, TMDX belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
- TMDX has a better Return On Invested Capital (8.75%) than 88.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of TMDX (16.20%) is better than 93.01% of its industry peers.
- Looking at the Operating Margin, with a value of 16.94%, TMDX belongs to the top of the industry, outperforming 87.63% of the companies in the same industry.
- TMDX's Gross Margin of 60.28% is fine compared to the rest of the industry. TMDX outperforms 61.83% of its industry peers.
- In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
- TMDX has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for TMDX has been increased compared to 5 years ago.
- The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 6.02 indicates that TMDX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of TMDX (6.02) is better than 81.18% of its industry peers.
- The Debt to FCF ratio of TMDX is 4.24, which is a neutral value as it means it would take TMDX, 4.24 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 4.24, TMDX belongs to the best of the industry, outperforming 80.11% of the companies in the same industry.
- A Debt/Equity ratio of 1.43 is on the high side and indicates that TMDX has dependencies on debt financing.
- The Debt to Equity ratio of TMDX (1.43) is worse than 78.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 6.02 |
ROIC/WACC0.91
WACC9.65%
2.3 Liquidity
- TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Current ratio value of 7.69, TMDX belongs to the best of the industry, outperforming 88.17% of the companies in the same industry.
- A Quick Ratio of 7.13 indicates that TMDX has no problem at all paying its short term obligations.
- TMDX has a Quick ratio of 7.13. This is amongst the best in the industry. TMDX outperforms 88.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
- TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.77%, which is quite impressive.
- Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 41.20%.
- TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
- TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.25% yearly.
- The Revenue is expected to grow by 21.23% on average over the next years. This is a very strong growth
EPS Next Y163.58%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 58.04, which means the current valuation is very expensive for TMDX.
- 68.28% of the companies in the same industry are more expensive than TMDX, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.38. TMDX is valued rather expensively when compared to this.
- TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 48.52.
- Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than 69.35% of the companies in the same industry.
- TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 24.29, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.04 | ||
| Fwd PE | 48.52 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 67.74% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, TMDX is valued a bit cheaper than the industry average as 75.81% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.62 | ||
| EV/EBITDA | 40.64 |
4.3 Compensation for Growth
- TMDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- TMDX's earnings are expected to grow with 53.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
- No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
143.37
-0.32 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners111.19%
Inst Owner Change0.02%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.90B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.84 (3.82%)
Short Float %21.09%
Short Ratio7.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)1.04%
PT rev (3m)-0.4%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)1.27%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)10.22%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.04 | ||
| Fwd PE | 48.52 | ||
| P/S | 8.65 | ||
| P/FCF | 40.62 | ||
| P/OCF | 27.47 | ||
| P/B | 13.79 | ||
| P/tB | 14.34 | ||
| EV/EBITDA | 40.64 |
EPS(TTM)2.47
EY1.72%
EPS(NY)2.95
Fwd EY2.06%
FCF(TTM)3.53
FCFY2.46%
OCF(TTM)5.22
OCFY3.64%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.35
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 6.02 |
F-Score7
WACC9.65%
ROIC/WACC0.91
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.58%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
Can you provide the valuation status for TRANSMEDICS GROUP INC?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
How financially healthy is TRANSMEDICS GROUP INC?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.